-
CDE issued a notice of "Technical Guidelines for the Evaluation of Similarity of Biosimilars and the Extrapolation of Indications"
Time of Update: 2021-07-26
Announcement of the Center for Drug Evaluation of the National Food and Drug Administration on Issuing the Technical Guidelines for Similarity Evaluation and Indication Extrapolation of Biosimilar Drugs (No.
-
Wan Yanhuan, deputy general manager of Kangyuan Pharmaceutical, resigns
Time of Update: 2021-07-26
recently received a written resignation report from the company’s deputy general manager, Mr.
Wan Yanhuan resigned from the position of deputy general manager of the company, and Mr.
Wan Yanhuan will no longer hold any position in the company .
-
Four batches and five rounds of nationally sourced varieties are compared. How long will it take to wait for the centralized procurement of biological medicines and Chinese patent medicines?
Time of Update: 2021-07-26
According to the statistics of Yaozhi data, up to now, the state has organized 4+7 pilot projects, 4+7 expansion, the second batch, third batch, and fourth batch of centralized procurement, a total of four batches and five rounds of national drug concentration.
-
Once banned from selling "star drugs", now they are still jumping in the corner
Time of Update: 2021-07-25
Recently, a typical case jointly issued by the Supreme People’s Procuratorate, the State Administration of Market Supervision, and the State Food and Drug Administration revealed that Han Moumou and Hong Moumou mixed sibutramine, which is prohibited by the state, into weight-loss coffee and published it on the Internet.
-
The State Food and Drug Administration has conditionally approved Cansino New Crown Vaccine and Sinopharm Zhongsheng New Crown Vaccine
Time of Update: 2021-07-25
The State Food and Drug Administration requires the holder of the vaccine marketing license to continue to carry out relevant research work, complete the conditional requirements, and submit the follow-up research results in time .
-
National Health Commission: Comprehensive research on the inclusion of HPV vaccination in the National Immunization Program
Time of Update: 2021-07-25
At the National Two Sessions in 2020, many representatives and committee members submitted suggestions and proposals, calling for the realization of the national planned immunization (free inoculation) of HPV (human papillomavirus) vaccine for girls of school age in China as soon as possible .
-
The first wave of salary adjustment plans for pharmaceutical companies in 2021 is coming!
Time of Update: 2021-07-25
However, in addition to the good news of the salary increase, there is also news that Huizhi reduced the county travel subsidy from 2,600 to 1,150 in February this year .
-
Huaxi Biotech hires Gao Yi as the company's deputy general manager
Time of Update: 2021-07-25
2 19, Huaxi Sheng was announced that the company held its twenty-first session of the Meeting of the Board of Directors considered and adopted the "motion on the appointment of senior executives," agreed to hire Ms.
Gao Yi's duties and contributions in the company and with reference to the industry level .
-
To benefit billions of people with presbyopia Essilor Wanlilu, the father of progressive lenses dies
Time of Update: 2021-07-25
The Wanlilu® progressive lens invented by Bernard Metenaz has improved the lives of hundreds of millions of people with presbyopia all over the world, and is a revolutionary and great invention in the optics industry .
-
The first in the world! Deliberately infected with the new crown "testing the drug", the humanitarian glory appears?
Time of Update: 2021-07-25
" It is reported that 90 volunteers need to "test the virus with their bodies" to help scientific researchers understand the virus and facilitate follow-up research on vaccines and treatments to improve epidemic prevention measures .
-
4+7 varieties are purchased in quantity again!
Time of Update: 2021-07-24
Judging from the information circulating this time, the first batch of 4+7 variety and quantity procurement plans organized by the locality have been upgraded and optimized, and the competitive nature of comprehensive bidding indicators has been emphasized from the two aspects of the drug dimension and the enterprise dimension .
-
Announcement of the State Food and Drug Administration on Issuing the Catalogue of Reference Preparations for Generic Drugs (Thirty-sixth Batch) (No. 7 of 2021)
Time of Update: 2021-07-24
After review and determination by the Expert Committee of the Quality and Efficacy Consistency Evaluation of Generic Drugs of the National Medical Products Administration, the catalogue of generic dr
-
Announcement of the State Food and Drug Administration on Issuing the Catalogue of Generic Drug Reference Preparations (Thirty-eighth Batch) (No. 18 of 2021)
Time of Update: 2021-07-24
After review and determination by the Expert Committee of the Quality and Efficacy Consistency Evaluation of Generic Drugs of the National Medical Products Administration, the catalogue of generic dr
-
Announcement of the State Food and Drug Administration on Issuing the Catalogue of Generic Drug Reference Preparations (Thirty-fourth Batch) (No. 89 of 2020)
Time of Update: 2021-07-24
After review and determination by the Expert Committee of the Quality and Efficacy Consistency Evaluation of Generic Drugs of the National Medical Products Administration, the catalogue of generic drug reference preparations (the 34th batch) is now released .
Hereby inform .
-
The Comprehensive Department of the State Food and Drug Administration publicly solicits opinions on the "Administrative Measures for the Registration of Licensed Pharmacists (Draft for Comment)
Time of Update: 2021-07-24
In order to improve the registration management system of licensed pharmacists, the State Food and Drug Administration revised the "Interim Measures for the Administration of Licensed Pharmacists Registration" (Guoyao Guanren [2000] No.
156) and formed the "Administrative Measures for the Registration of Licensed Pharmacists (Draft for Solicitation of Comments)".
-
Announcement of the State Food and Drug Administration on the issuance of "Changes to Listed Chinese Medicines and Requirements for Application Information" (No. 19 of 2021)
Time of Update: 2021-07-24
In order to cooperate with the implementation of the "Administrative Measures for Drug Registration", the State Drug Administration has organized and formulated the "Changes to Listed Chinese Medicines and Requirements for Application Information", which is hereby released .
Attachment: Changes to listed Chinese medicines and requirements for application materials State Food and Drug Administration February 23, 2021
-
Announcement of the State Food and Drug Administration on Issuing the Principles for the Classification of Recombinant Collagen Medical Products (No. 27 of 2021)
Time of Update: 2021-07-24
In order to further strengthen the supervision and management of recombinant collagen medical products and promote the high-quality development of the industry, the State Food and Drug Administration has organized and formulated the "Principles for the Classification and Definition of Recombinant Collagen Medical Products", which is hereby announced .
27 of 2021 of the State Drug Administration
-
Announcement of the State Food and Drug Administration on Issuing the Catalogue of Generic Drug Reference Preparations (Fortieth Batch) (No. 23 of 2021)
Time of Update: 2021-07-24
After review and determination by the Expert Committee of Quality and Efficacy Consistency Evaluation of Generic Drugs of the National Medical Products Administration, the catalogue of generic drug reference preparations (the fortieth batch) is now released .
-
Interview with Liu Guoen, leader of the expert group of medical insurance pharmacoeconomics estimation: reducing personal payment burden is difficult to solve at one time
Time of Update: 2021-07-22
Liu Guoen: In the process of adjusting the medical insurance catalogue, pharmacoeconomics mainly evaluates the differences in clinical effects, side effects, and comprehensive drug costs between the declared drugs and the reference drugs .
-
International Rare Disease Day: Use science to care for these special groups
Time of Update: 2021-07-22
Marginal zone lymphoma (MZL) is a group of indolent B-cell lymphoma diseases, accounting for approximately 8% of non-Hodgkin's lymphoma (NHL) patients .
ICP-723 has the potential to provide broad-spectrum anti-cancer therapy for patients with solid tumors with NTRK gene fusion, and is currently conducting phase I clinical studies in China .
